US considers Pfizer COVID-19 vaccine approval

Pfizer scientist Kathrin Jansen told the panel this was a result of the innovative messenger RNA technology behind the vaccine, an approach that has never before been approved.

Pharmaceutical giant Pfizer is conducting a COVID-19 vaccine trial in conjunction with BioNTech. Picture: Supplied.

WASHINGTON, United States - US experts met on Thursday to assess whether to grant emergency approval for Pfizer-BioNTech's COVID-19 vaccine and allow America to become the next country to move ahead with mass immunization.

The independent committee of experts convened by the Food and Drug Administration (FDA) will hold a non-binding vote at the end of the day, and the US regulator will determine after that whether to issue an emergency use authorization (EUA).

The arguments in favor seem to be overwhelming -- it has already been greenlit by Britain and other countries -- and the full results of a huge clinical trial of the vaccine were published Thursday in the New England Journal of Medicine, another major milestone.

These confirmed it was 95% effective with no serious safety issues, an outcome that was described in an accompanying editorial as a "triumph."

Pfizer scientist Kathrin Jansen told the panel this was a result of the innovative messenger RNA technology behind the vaccine, an approach that has never before been approved.

"The immune responses induced by the mRNA are similar to what you may get in response to natural infection -- but, of course, the mRNA vaccine is non-infectious and cannot cause disease," she said.

Nevertheless, the two dozen voting members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) were mulling outstanding issues closely in a live streamed event held over the course of the day.

These include difficult questions like when people who were on the placebo-arm of the trial should receive the vaccine, a tricky debate that weighs the need for more controlled data against paying back altruistic volunteers for their service.

DISTRIBUTION SOON

If the panel votes in favor, as they are expected to, FDA approval could come at any time over the next few days, health secretary Alex Azar said Wednesday, with rollout as early as next week.

In a trial of almost 44,000 people, there were two deaths in the vaccine arm and four in the placebo, with none thought to be related to BNT162b2, the technical name for the jab.

The most common side effects were run of the mill for vaccines, such as injection site reactions, fatigue and headache.

But Britain on Wednesday reported that two health care workers developed significant allergic reactions to the vaccine as the country rolled out its massive drive Tuesday.

The FDA will therefore include a warning label on the vaccine if it's approved, the agency's Marion Gruber said, ahead of further study.

And, according to the FDA, there were four people among the vaccine arm's subjects who developed Bell's palsy -- a facial paralysis condition that is usually temporary -- but none in the placebo group.

That's about the rate at which it occurs in the general population, but the FDA recommended collecting more follow-up data.

The FDA has been praised for its diligence and transparency, which has helped restore its reputation that took a hit earlier on in the pandemic over perceptions that President Donald Trump had leaned on it to issue questionable authorizations.

HIGH EFFICACY

The first vaccine dose begins to protect patients ten days after injection, and the booster shot reduces the risk of developing COVID-19 by 95% compared to being unvaccinated.

The best news is that it also seems to stop the most severe forms of the disease, said Yale vaccinologist Saad Omer.

Unknowns include how long immunity will last -- top US government scientist Moncef Slaoui said Wednesday he was confident that the injection would create long-term immune memory.

Another question is how well the shot will stop virus transmission, and whether it will be effective in children, pregnant women, and the immunocompromised.

The next step is distribution, which is being coordinated by the federal government but handled by private partners like FedEx.

The first wave of shipments will include around three million doses, which will be transported from the Pfizer plant in Kalamazoo, Michigan in dry ice containers kept at -70 degrees Celsius (-94 degrees Fahrenheit).

From there it will ship out across the US, ready to be injected into the arms of long-term care facility residents and health care workers -- the two groups standing at the front of a long line of Americans waiting their turns.

Download the EWN app to your iOS or Android device.